Myeloid malignancies and the marrow microenvironment: Some recent studies in patients with MDS

Current Cancer Therapy Reviews

Volumn 5, Issue 4, 2009, Pages 310-314

  Marcondes, A Mario ^a,b   Ramakrishnan, Aravind ^a,c   Deeg, H Joachim ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

IL 32; Marrow stroma; MDS; Telomere

Indexed keywords

CYTOKINE; GELATINASE B; INTERLEUKIN 32; LENALIDOMIDE; MESSENGER RNA; RETINOIC ACID RECEPTOR GAMMA; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; AUTOIMMUNITY; BONE MARROW; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOKINE RELEASE; GENE EXPRESSION REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA CELL; MALIGNANT TRANSFORMATION; MICROENVIRONMENT; MOLECULAR INTERACTION; MYELODYSPLASTIC SYNDROME; NEGATIVE FEEDBACK; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TELOMERE;

EID: 71749102623     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339409789712681     Document Type: Review

References (45)

1. Duhrsen U, Hossfeld DK. Stromal abnormalities in neoplastic bone marrow diseases (Review). Ann Hematol 1996; 73: 53-70. (Pubitemid 26270950)
2. Walkley CR, Olsen GH, Dworkin S, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell 2007; 129: 1097-1110 (Pubitemid 46908696)
3. El-Cheikh J, Michallet M, Nagler A, et al. HIgh response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008; 93: 455-458
4. Gadi VK, Nash RA. Hematopoietic stem cell transplantation. In: Greer JP, Foerster J, Rodgers GM, et al., Eds. Wintrobe's Clinical Hematology. 10th ed. Baltimore, MD: Lippincott Williams & Wilkins 1999.
5. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995; 85: 3636-3645
6. Simmons PJ, Przepiorka D, Thomas ED, Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature1987; 328: 429-432
7. Perkins S, Fleischman RA. Hematopoietic microenvironment. Origin, lineage, and transplantability of the stromal cells in long-term bone marrow cultures from chimeric mice. J Clin Invest 1988; 81: 1072-1080 (Pubitemid 18128070)
8. Lennon JE, Micklem HS. Stromal cells in long-term murine bone marrow culture: FACS studies and origin of stromal cells in radiation chimeras. Exp Hematol 1986; 12: 287-292 (Pubitemid 16047669)
9. O'Reilly RJ, Keever C, Kernan NA, et al. HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplant Proc 1987; 19: 55-60. (Pubitemid 18052473)
10. Awaya N, Rupert K, Bryant E, Torok-Storb B. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol 2002; 30: 937-942 (Pubitemid 34838895)
11. Blau O, Hofmann WK, Baldus CD, et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp Hematol 2007; 35: 221-229 (Pubitemid 46135819)
12. Flores-Figueroa E, Arana-Trejo RM, Gutierrez-Espindola G, Perez-Cabrera A, Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 2005; 29: 215-224 (Pubitemid 39647516)
13. Stirewalt DL, Mhyre AJ, Marcondes M, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol 2008; 140: 444-453
14. Gersuk GM, Beckham C, Loken MR, et al. A role for tumor necrosis factor-a, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998; 103: 176-188 (Pubitemid 28470816)
15. Ying SX, Seal S, Abbassi N, et al. Differential effects of bexatrone on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. Leuk Lymphoma 2007; 48: 1003-1014 (Pubitemid 47161572)
16. Goda C, Kanaji T, Kanaji S, et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 2006; 18: 233-240 (Pubitemid 43160136)
17. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by upregulation of anti-apoptotic proteins. Leukemia 2002; 16: 1713-1724 (Pubitemid 35050102)
18. Mundle SD, Venugopal P, Cartlidge JD, et al. Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood 1996; 88: 2640-2647 (Pubitemid 26327516)
19. Raza A, Mundle S, Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. (Review). Int J Hematol 1996; 63: 265-278 (Pubitemid 26173932)
20. Mundle SD, Reza S, Ali A, et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999; 140: 201-207 (Pubitemid 29251332)
21. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-1434 (Pubitemid 32183769)
22. Molnar L, Berki T, Hussain A, Nemeth P, Losonczy H. Detection of TNFalpha expression in the bone marrow and determination of TNFalpha production of peripheral blood mononuclear cells in myelodysplastic syndrome. Pathol Oncol Res 2000; 6: 18-23. (Pubitemid 30262774)
23. Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 1992; 148: 597-603
24. Deeg HJ, Beckham C, Loken MR, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000; 37: 405-414 (Pubitemid 30162551)
25. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005; 22: 131-142
26. Roth C, Rothlin C, Riou S, Raulet DH, Lemke G. Stromal-cell regulation of natural killer cell differentiation. J Mol Med 2007; DOI: 10.1007/s00109-007- 0195-0
27. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms (Review). Blood 2002; 100: 2292-2302
28. Flores-Figueroa E, Montesinos JJ, Flores-Guzman P, et al. Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk Res 2008; 32: 1407-1416
29. Iwata M, Pillai M, Ramakrishnan A, et al. Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity. Blood 2007; 109: 85-92. (Pubitemid 46053047)
30. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001; 97: 3354-3360
31. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001; 276 : 43503-43508 (Pubitemid 37383907)
32. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002; 100: 3495-3503 (Pubitemid 35303916)
33. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000; 96: 3374-3380 (Pubitemid 30836314)
34. Deeg HJ. Marrow stroma in MDS: culprit or bystander? Leuk Res 2002; 26: 687-688
35. Marsh JC, Harhalakis N, Dowding C, Laffan M, Gordon-Smith EC, Hows JM. Recurrent graft failure following syngeneic bone marrow transplantation for aplastic anaemia. Bone Marrow Transplant 1989; 4: 581-585 (Pubitemid 19236595)
36. Witherspoon RP, Buckner CD, Thomas ED, et al. Results of allogeneic marrow transplantation in patients transplanted for acute leukemia: a long-term follow-up. In: Hagenbeek A, Lowenberg B, Eds. Minimal Residual Disease in Acute Leukemia. Dodrecht: Martinus Nijhoff 1986; pp. 318-322
37. Lawler M, Locasciulli A, Longoni D, Schiro R, McCann SR. Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia (Review) [erratum appears in Bone Marrow Transplant. 2002 May; 29(9): 805]. Bone Marrow Transplant 2002; 29: 453-456
38. McCann SR, Bacigalupo A, Gluckman E, et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994; 13: 233-237 (Pubitemid 24065946)
39. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim S-H, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 2008; 105: 2865-2870
40. Boultwood J, Fidler C, Kusec R, et al. Telomere length in myelodysplastic syndromes. Am J Hematol 1997; 56: 266-271
41. Fern L, Pallis M, Ian CG, Seedhouse C, Russell N, Byrne J. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol 2004; 126: 63-71. (Pubitemid 38859483)
42. Ohyashiki JH, Ohyashiki K, Fujimura T, et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994; 54: 3557-3560 (Pubitemid 24225983)
43. Ohyashiki K, Iwama H, Yahata N, et al. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation (Review). Leuk Lymphoma 2001; 42: 291-299 (Pubitemid 32725585)
44. Sieglova Z, Zilovcova S, Cermak J, et al. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis? Leuk Res 2004; 28: 1013-1021
45. Marcondes AM, Bair S, Rabinovitch PS, Gooley T, Deeg HJ, Risques RA. No telomere shortening in marrow stroma from patients with MDS. Ann Hematol 2009; 88(7): 623-628